Autres langues Harmony Biosciences Holdings, Inc.

Actions

HRMY

US4131971040

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
29,03 ^USD	-0,96 %		-3,68 %	-10,12 %

30/04	Harmony Biosciences acquiert Epygenix Therapeutics ; les actions augmentent	MT
30/04	Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy	01/05
Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise	30/04
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	30/04
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q1 EPS $0.88, vs. Street Est of $0.78	30/04
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy	30/04
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	30/04
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets	30/04
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024	16/04
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST	12/04
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	11/04
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	03/04
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME	03/04
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	03/04
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE	26/03
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	19/03
Harmony Biosciences Certified as a Great Place to Work for Sixth Consecutive Year, Underscoring Ongoing Commitment to Employee Satisfaction and Growth	07/03
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES	28/02
HARMONY BIOSCIENCES EXPANDS COMMITMENT TO THE RARE NEUROLOGICAL DISEASE COMMUNITY WITH CALL FOR PROGRESS AT THE HEART AND PATIENTS AT THE HEART APPLICATIONS	27/02
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	22/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Harmony Biosciences Holdings, Inc.

Actions

HRMY

US4131971040

Autres langues

Filtres